Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: pro

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Debate on cardiac implantable electronic device therapy Device Therapy EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

ESC 365 is supported by

ESC 365 is supported by